Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Syros Pharmaceuticals, Inc.    SYRS

SYROS PHARMACEUTICALS, INC.

(SYRS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
12.07(c) 11.6(c) 12.25(c) 13.83(c) 14.1 Last
985 411 535 738 597 405 817 356 803 008 Volume
-1.39% -3.89% +5.60% +12.90% +1.95% Change
More quotes
Financials (USD)
Sales 2020 12,1 M - -
Net income 2020 -79,1 M - -
Net Debt 2020 - - -
P/E ratio 2020 -8,10x
Yield 2020 -
Sales 2021 9,96 M - -
Net income 2021 -86,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,51x
Yield 2021 -
Capitalization 777 M 777 M -
Capi. / Sales 2020 64,3x
Capi. / Sales 2021 78,0x
Nbr of Employees 83
Free-Float 93,4%
More Financials
Company
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefining the power of small molecules to control the expression of genes. It is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a... 
More about the company
Notations Surperformance© of Syros Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SYROS PHARMACEUTICALS, INC.
01/11SYROS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Result..
AQ
01/11SYROS PHARMACEUTICALS : Announces Strategic Priorities and Expected Milestones
BU
01/08Equities Move Mostly Higher in Morning Trading Amid Expectations for US Econo..
MT
01/08SYROS PHARMACEUTICALS : Files Shelf for Up to 14.1 Million Common Shares on Beha..
MT
01/07SYROS PHARMACEUTICALS : CORRECTING and REPLACING Syros to Present at 39th Annual..
BU
2020SYROS PHARMACEUTICALS, INC. : Creation of a Direct Financial Obligation or an Ob..
AQ
2020INSIDER TRENDS : Syros Pharmaceuticals Insider Reports Option Conversion Extendi..
MT
2020SYROS PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (f..
AQ
2020SYROS PHARMACEUTICALS : Closes $90.5 Million Strategic Financing
BU
2020Wedbush Adjusts Syros Pharmaceuticals' Price Target to $8 From $10, Maintains..
MT
2020SYROS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unregi..
AQ
2020SYROS PHARMACEUTICALS : Presents New Data From Phase 2 Clinical Trial of SY-1425..
BU
2020SYROS PHARMACEUTICALS : Acquires Clinical-Stage Drug Candidate for Acute Promyel..
BU
2020SYROS PHARMACEUTICALS : to Present at Piper Sandler 32nd Annual Virtual Healthca..
AQ
2020SYROS PHARMACEUTICALS : to Present at Piper Sandler 32nd Annual Virtual Healthca..
BU
More news
News in other languages on SYROS PHARMACEUTICALS, INC.

- No features available -

More news
Analyst Recommendations on SYROS PHARMACEUTICALS, INC.
More recommendations
Chart SYROS PHARMACEUTICALS, INC.
Duration : Period :
Syros Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYROS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 17,43 $
Last Close Price 13,83 $
Spread / Highest target 44,6%
Spread / Average Target 26,0%
Spread / Lowest Target -6,00%
EPS Revisions
Managers and Directors
NameTitle
Nancy A. Simonian President, Chief Executive Officer & Director
Peter Wirth Chairman
Joseph J. Ferra Chief Financial Officer
Eric R. Olson Chief Scientific Officer
David A. Roth Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SYROS PHARMACEUTICALS, INC.27.47%777
CSL LIMITED-4.30%95 982
SAMSUNG BIOLOGICS CO.,LTD.-1.21%49 217
BIOGEN INC.14.47%43 131
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-5.54%34 529
ALEXION PHARMACEUTICALS, INC.0.13%34 282